Table 1 Characteristics of 5 patients with COVID-19 and colorectal cancer and 20 matched patients with COVID-19 without cancer.

Sex

1

 Female

2 (40)

 Male

3 (60)

Age

1

 >65 y

3 (60)

 ≤65 y

2 (40)

 0

1 (20)

1

 1

3 (60)

 2

0 (0)

 3

1 (20)

 Diabetes

1 (20)

1

 Hypertension

3 (60)

1

 Coronary heart disease

1 (20)

0.504

 Cerebrovascular disease

0 (0)

1

 Renal disease

1 (20)

1

 Liver disease

0 (0)

/

 I

2 (40)

 II

2 (40)

 III

1 (20)

 Colon

1 (20)

 Rectum

4 (80)

 White blood cell count, <4 × 10⁹/L

1 (20)

1

 Lymphocyte count, <0.8 × 10⁹/L

4 (80)

0.023

 Neutrophil count, <1.8 × 10⁹/L

1 (20)

0.367

 Platelet count, <100 × 10⁹/L

0 (0)

1

 Hemoglobin, <115 g/L

1 (20)

1

 Hypersensitive C-reactive protein, >6 mg/L

5 (100)

0.009

 Procalcitonin, >0.05 ng/mL

4 (80)

0.341

 Lactate dehydrogenase, >300 U/L

3 (60)

0.070

 D-dimer, >0.5 μg/mL

3 (60)

0.358

 Alanine aminotransferase, > 40 U/L

0 (0)

1

 Aspartate aminotransferase, >40 U/L

1 (20)

1

 Total protein, <60 g/L

2 (40)

0.597

 Albumin, <34 g/L

3 (60)

1

 Globulin, <26 g/L

0 (0)

0.549

 Creatinine, >120 μmol/L

1 (20)

1

 Blood urea nitrogen, >8.8 mmol/L

1 (20)

1

 CO₂ CP, >29 mmol/L

1 (20)

1

 Pulse rate, ≥90 bpm

2 (40)

1

 Respiratory rate, >20 times/min

4 (80)

0.040

 SpO₂ (%), <93%

2 (40)

0.562

 Body temperature, °C

5 (100)

1

 Cough

4 (80)

1

 Sputum

1 (20)

1

 Hemoptysis

0 (0)

1

 Shortness of breath

3 (60)

1

 Diarrhea

0 (0)

1

 Nausea or vomiting

0 (0)

1

 Fatigue

3 (60)

0.358

 Myalgia

0 (0)

1

 Anorexia

0 (0)

1

 Sore throat

1 (20)

0.200

 CT findings (bilateral)

5 (100)

1

 Antibiotics (yes)

4 (80)

0.504

 Antiviral therapy (yes)

3 (60)

0.358

 Immunomodulators (yes)

3 (60)

0.623

 Systemic glucocorticoids (yes)

4 (80)

0.160

 Mechanical ventilation

1 (20)

0.367

COVID-19 > 30 days

3 (60)

0.358

Treatment in intensive care unit

1 (20)

0.367

Clinical outcome (death)

1 (20)

0.367